Table 3. Efficacy, safety and development status of targeted therapies for EGFR exon20ins–mutant NSCLC [12, 36, 41, 42].
| Drug (Trial identifier) | Type | ORR (%) | Median PFS (months) | CNS Activity | Route | Key AEs (≥ Grade 3) | Development Status |
|---|---|---|---|---|---|---|---|
| Amivantamab (NCT02609776) | Bispecific EGFR-MET monoclonal antibody | 40 | 8.3 | Limited | IV infusion | Rash (4%), IRR (3%), Paronychia (1%) | FDA-approved; ongoing phase III trials |
| Mobocertinib (NCT02716116) | Oral EGFR TKI | 28 | 7.3 | Limited | Oral | Diarrhea (16%), QTc prolongation (3%) | Withdrawn from market (2023) |
| Sunvozertinib (NCT05712902) | Oral EGFR TKI (3rd-gen, irreversible) | 61 | 7.6 | Promising | Oral | Blood creatine Phosphokinase increased (17%), Diarrhea (8%), Anemia(6%) | In development; ongoing trials |
| Poziotinib (NCT03318939) | Oral EGFR/HER2 TKI | 27.8 | 5.5 | Limited | Oral | Rash (48%), Diarrhea (25%), Stomatitis (24%) | Development discontinued |
EGFR = Epidermal Growth Factor Receptor; NSCLC = Non–Small Cell Lung Cancer; ORR = Objective Response Rate; PFS = Progression-Free Survival; CNS = Central Nervous System; IV = Intravenous; IRR = Infusion-Related Reaction; TKI = Tyrosine Kinase Inhibitor
Adverse events (AEs) reported are grade ≥3 where available. Data are derived from single-arm clinical trials unless otherwise specified. Trial identifiers (NCT numbers) correspond to ClinicalTrials.gov registry entries.
Note: Mobocertinib data are based on the original EXCLAIM trial (NCT02716116) in previously treated patients; data from EXCLAIM-2 are not included in this table. Original table